Lotronex (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023 - New Study Released

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Lotronex (alosetron) is indicated for women with severe IBS-D who have chronic IBS, have had anatomic or biochemical abnormalities of the GI tract excluded, and have not responded adequately to conventional therapy. GlaxoSmithKline (GSK) initially introduced this product into the US market in February 2000. However, a few months later, in November 2000, the company decided to withdraw the drug due to it being linked with undesirable adverse effects, such as ischemic colitis (restricted blood flow to the colon), severe constipation, and three fatalities.

Full Report Details at
- http://www.fastmr.com/prod/966194_lotronex_irritable_bowel_syndrome_forecast_and.aspx?afid=301

Scope

* Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Lotronex including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Lotronex for the top country from 2013 to 2023.
* Sales information covered for the US.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return.
* Stay ahead of the competition by understanding the changing competitive landscape for IBS.
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
* Make more informed business decisions from insightful and in-depth analysis of Lotronex performance.
* Obtain sales forecast for Lotronex from 2013-2023 in top country (the US).

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: Irritable Bowel Syndrome - Japan Drug Forecast and Market Analysis to 2023
- Plecanatide (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023